How GLP-1 analogs are reshaping diabetes care and obesity treatment and unlocking potential in cardiovascular, inflammatory, ...

The following is a summary of “Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a ...

Type 1 diabetes is an autoimmune condition associated with genetics and may develop suddenly. Type 2 diabetes often develops over time, with obesity and a lack of exercise as the main risk factors.

HealthDay News — Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days before total joint arthroplasty can minimize risks for complications, according to a study presented at ...

Novo Nordisk announced Monday a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the Danish company is currently the leading player. Novo Nordisk said it’s ...

Manufactured by Novo Nordisk, semaglutide is the newest in a family of glucagon-like peptide-1 (GLP-1) receptor agonists used most commonly to treat type II diabetes. To date, the results of ...

Use of GLP-1 RAs was associated with lower incidence of death-censored graft loss and lower mortality among kidney transplant recipients with diabetes. HealthDay News — Glucagon-like peptide-1 ...

All patients remained adherent to the GLP-1 medication through 8 months. "I believe combining the Allurion Balloon with low-dose GLP-1 therapy has several advantages," said Dr. Luigi Flagiello ...

New solution leverages Quantum Health’s clinical expertise, health coaching and holistic care coordination combined with Vida Health’s evidence-based prescribing to optimize GLP-1 utilization ...

Many employers are facing challenges in incorporating high-cost GLP-1 medications, such as Mounjaro, Ozempic, Rybelsus, Trulicity, and Wegovy, into their group health plans, as they must balance ...

The GLP-1 class of drugs used to treat diabetes and obesity may have the potential to benefit huge swaths of the public, but ongoing employer concerns over cost and a lack of patient adherence ...